$AKCA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AKCEA THERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AKCEA THERAPEUTICS, INC.. Get notifications about new insider transactions in AKCEA THERAPEUTICS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14 2020 | AKCA | AKCEA THERAPEUTICS ... | IONIS PHARMACEUTICALS INC | 10% Owner | Buy | P | 18.15 | 21,237,715 | 385,464,527 | 98,322,397 | 77.1 M to 98.3 M (+27.55 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | PRICE MICHAEL DENNIS | Chief Financial Off ... | Option Exercise | D | 14.78 | 300,000 | 4,434,000 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | PRICE MICHAEL DENNIS | Chief Financial Off ... | Sell | U | 18.15 | 50,000 | 907,500 | 0 | 50 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Option Exercise | D | 12.76 | 7,500 | 95,700 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Option Exercise | D | 16.99 | 13,750 | 233,613 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Sell | U | 18.15 | 26,532 | 481,556 | 0 | 26.5 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | D | 12.76 | 34,200 | 436,392 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | D | 17.38 | 13,701 | 238,123 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | D | 17.38 | 299 | 5,197 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | D | 12.21 | 32,751 | 399,890 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | D | 12.21 | 143,374 | 1,750,597 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Sell | U | 18.15 | 52,012 | 944,018 | 0 | 52 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Option Exercise | D | 12.76 | 34,200 | 436,392 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Option Exercise | D | 17.94 | 300,000 | 5,382,000 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Sell | U | 18.15 | 66,800 | 1,212,420 | 0 | 66.8 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | D | 13.29 | 250,000 | 3,322,500 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Andrews William T. | Chief Medical Offic ... | Sell | U | 18.15 | 37,500 | 680,625 | 0 | 37.5 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | D | 12.76 | 200,000 | 2,552,000 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | D | 12.76 | 120,000 | 1,531,200 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Sell | U | 18.15 | 242,978 | 4,410,051 | 0 | 243 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | YANG MICHAEL J. | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | D | 12.76 | 200,000 | 2,552,000 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | D | 12.21 | 52,837 | 645,140 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | D | 12.76 | 120,000 | 1,531,200 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Sell | U | 18.15 | 242,978 | 4,410,051 | 0 | 243 K to 0 (-100.00 %) |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | YANG MICHAEL J. | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | D | 12.21 | 52,837 | 645,140 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | D | 17.94 | 53,000 | 950,820 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | KLEIN JOSEPH III | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Hochberg Elaine | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Hochberg Elaine | Director | Option Exercise | D | 12.21 | 52,837 | 645,140 | 0 | |
| Oct 13 2020 | AKCA | AKCEA THERAPEUTICS ... | PARSHALL B LYNNE | Director | Option Exercise | D | 16.14 | 26,400 | 426,096 | 0 | |
| Sep 24 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Sell | S | 18.12 | 319 | 5,780 | 26,532 | 26.9 K to 26.5 K (-1.19 %) |
| Sep 24 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Sell | S | 18.12 | 720 | 13,046 | 52,012 | 52.7 K to 52 K (-1.37 %) |
| Sep 24 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Sell | S | 18.12 | 8,709 | 157,807 | 242,978 | 251.7 K to 243 K (-3.46 %) |
| Sep 02 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Grant | A | 14.40 | 1,104 | 15,896 | 251,687 | 250.6 K to 251.7 K (+0.44 %) |
| Jul 20 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Sell | S | 12.50 | 263 | 3,288 | 26,851 | 27.1 K to 26.9 K (-0.97 %) |
| Jul 10 2020 | AKCA | AKCEA THERAPEUTICS ... | Andrews William T. | Chief Medical Offic ... | Option Exercise | A | 13.29 | 250,000 | 3,322,500 | 250,000 | |
| Jul 10 2020 | AKCA | AKCEA THERAPEUTICS ... | Andrews William T. | Chief Medical Offic ... | Grant | A | 0.00 | 37,500 | 0 | 37,500 | 0 to 37.5 K |
| May 19 2020 | AKCA | AKCEA THERAPEUTICS ... | PRICE MICHAEL DENNIS | Chief Financial Off ... | Option Exercise | A | 14.78 | 300,000 | 4,434,000 | 300,000 | |
| May 19 2020 | AKCA | AKCEA THERAPEUTICS ... | PRICE MICHAEL DENNIS | Chief Financial Off ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Grant | A | 0.00 | 12,500 | 0 | 27,114 | 14.6 K to 27.1 K (+85.53 %) |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | PARSHALL B LYNNE | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | YANG MICHAEL J. | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | Hochberg Elaine | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Apr 15 2020 | AKCA | AKCEA THERAPEUTICS ... | KLEIN JOSEPH III | Director | Option Exercise | A | 16.14 | 26,400 | 426,096 | 26,400 | |
| Mar 25 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Sell | S | 11.76 | 335 | 3,938 | 14,614 | 14.9 K to 14.6 K (-2.24 %) |
| Mar 25 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Sell | S | 11.75 | 779 | 9,153 | 52,732 | 53.5 K to 52.7 K (-1.46 %) |
| Mar 25 2020 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Sell | S | 11.75 | 3,198 | 37,579 | 61,602 | 64.8 K to 61.6 K (-4.94 %) |
| Mar 25 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Sell | S | 11.75 | 9,417 | 110,649 | 245,783 | 255.2 K to 245.8 K (-3.69 %) |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Option Exercise | A | 12.76 | 34,200 | 436,392 | 34,200 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Grant | A | 0.00 | 16,800 | 0 | 66,800 | 50 K to 66.8 K (+33.60 %) |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | A | 12.76 | 34,200 | 436,392 | 34,200 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Grant | A | 0.00 | 16,800 | 0 | 53,511 | 36.7 K to 53.5 K (+45.76 %) |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Option Exercise | A | 12.76 | 34,200 | 436,392 | 34,200 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Grant | A | 0.00 | 16,800 | 0 | 64,800 | 48 K to 64.8 K (+35.00 %) |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Option Exercise | A | 12.76 | 7,500 | 95,700 | 7,500 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | Patterson Joshua F. | General Counsel | Grant | A | 0.00 | 3,780 | 0 | 14,949 | 11.2 K to 14.9 K (+33.84 %) |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | A | 12.76 | 200,000 | 2,552,000 | 200,000 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Option Exercise | A | 12.76 | 109,800 | 1,401,048 | 109,800 | |
| Mar 23 2020 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Chief Executive Off ... | Grant | A | 0.00 | 55,200 | 0 | 255,200 | 200 K to 255.2 K (+27.60 %) |
| Feb 13 2020 | AKCA | AKCEA THERAPEUTICS ... | Salzman Amber | Director | Option Exercise | A | 17.94 | 53,000 | 950,820 | 53,000 | |
| Jan 16 2020 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Grant | A | 0.00 | 28,000 | 0 | 48,000 | 20 K to 48 K (+140.00 %) |
| Jan 16 2020 | AKCA | AKCEA THERAPEUTICS ... | MacLean Michael F | Chief Financial Off ... | Grant | A | 0.00 | 28,000 | 0 | 48,000 | 20 K to 48 K (+140.00 %) |
| Jan 03 2020 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Option Exercise | A | 16.99 | 57,000 | 968,430 | 57,000 | |
| Jan 03 2020 | AKCA | AKCEA THERAPEUTICS ... | MacLean Michael F | Chief Financial Off ... | Option Exercise | A | 16.99 | 57,000 | 968,430 | 57,000 | |
| Dec 19 2019 | AKCA | AKCEA THERAPEUTICS ... | IONIS PHARMACEUTICALS INC | 10% Owner | Buy | J | 0.00 | 6,873,344 | 0 | 77,094,682 | 70.2 M to 77.1 M (+9.79 %) |
| Dec 16 2019 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | A | 19.30 | 53,000 | 1,022,900 | 53,000 | |
| Dec 16 2019 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | A | 19.30 | 53,000 | 1,022,900 | 53,000 | |
| Dec 16 2019 | AKCA | AKCEA THERAPEUTICS ... | Yanni Barbara | Director | Option Exercise | A | 19.30 | 53,000 | 1,022,900 | 53,000 | |
| Dec 04 2019 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Option Exercise | A | 17.94 | 300,000 | 5,382,000 | 300,000 | |
| Dec 04 2019 | AKCA | AKCEA THERAPEUTICS ... | Howarth Alex G. | Chief Operating Off ... | Grant | A | 0.00 | 50,000 | 0 | 50,000 | 0 to 50 K |
| Oct 23 2019 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Option Exercise | A | 18.94 | 50,000 | 947,000 | 50,000 | |
| Oct 23 2019 | AKCA | AKCEA THERAPEUTICS ... | Jenne Kyle | Chief Commercial Of ... | Grant | A | 0.00 | 25,000 | 0 | 36,711 | 11.7 K to 36.7 K (+213.47 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 12.21 | 35,230 | 430,158 | 17,607 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 12.21 | 35,230 | 430,158 | 17,607 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 83,952 | 544,009 | 7,633 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 83,952 | 544,009 | 7,633 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 302,250 | 1,958,580 | 0 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 302,250 | 1,958,580 | 0 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 30,016 | 499,466 | 156,631 | 186.6 K to 156.6 K (-16.08 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 30,016 | 499,466 | 156,631 | 186.6 K to 156.6 K (-16.08 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 12.21 | 35,230 | 430,158 | 186,647 | 151.4 K to 186.6 K (+23.27 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 12.21 | 35,230 | 430,158 | 186,647 | 151.4 K to 186.6 K (+23.27 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 52,973 | 881,471 | 151,417 | 204.4 K to 151.4 K (-25.92 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 52,973 | 881,471 | 151,417 | 204.4 K to 151.4 K (-25.92 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 83,952 | 544,009 | 204,390 | 120.4 K to 204.4 K (+69.71 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 83,952 | 544,009 | 204,390 | 120.4 K to 204.4 K (+69.71 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 185,122 | 3,080,430 | 120,438 | 305.6 K to 120.4 K (-60.58 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Payment of Exercise | F | 16.64 | 185,122 | 3,080,430 | 120,438 | 305.6 K to 120.4 K (-60.58 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 302,250 | 1,958,580 | 305,560 | 3.3 K to 305.6 K (+9,131.42 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 302,250 | 1,958,580 | 305,560 | 3.3 K to 305.6 K (+9,131.42 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 12.21 | 205,479 | 2,508,899 | 102,740 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 145,303 | 941,563 | 13,209 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 1,711,079 | 11,087,792 | 0 | |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Payment of Exercise | F | 16.64 | 175,064 | 2,913,065 | 678,149 | 853.2 K to 678.1 K (-20.52 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 12.21 | 205,479 | 2,508,899 | 853,213 | 647.7 K to 853.2 K (+31.72 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Payment of Exercise | F | 16.64 | 95,156 | 1,583,396 | 647,734 | 742.9 K to 647.7 K (-12.81 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 145,303 | 941,563 | 742,890 | 597.6 K to 742.9 K (+24.31 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Payment of Exercise | F | 16.64 | 1,113,492 | 18,528,507 | 597,587 | 1.7 M to 597.6 K (-65.08 %) |
| Sep 30 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 1,711,079 | 11,087,792 | 1,711,079 | 0 to 1.7 M |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | O'Dea Louis | Chief Medical Offic ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | MacLean Michael F | Chief Financial Off ... | Grant | A | 0.00 | 20,000 | 0 | 20,000 | 0 to 20 K |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Interim Chief Execu ... | Option Exercise | A | 22.46 | 400,000 | 8,984,000 | 400,000 | |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | McDevitt Damien | Interim Chief Execu ... | Grant | A | 0.00 | 200,000 | 0 | 200,000 | 0 to 200 K |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | YANG MICHAEL J. | Director | Option Exercise | A | 22.46 | 53,000 | 1,190,380 | 53,000 | |
| Sep 23 2019 | AKCA | AKCEA THERAPEUTICS ... | KLEIN JOSEPH III | Director | Option Exercise | A | 22.46 | 53,000 | 1,190,380 | 53,000 | |
| Jul 17 2019 | AKCA | AKCEA THERAPEUTICS ... | Boyce Sarah | President | Sell | S | 23.52 | 1,819 | 42,783 | 19,888 | 21.7 K to 19.9 K (-8.38 %) |
| Jul 03 2019 | AKCA | AKCEA THERAPEUTICS ... | Boyce Sarah | President | Grant | A | 20.04 | 813 | 16,295 | 21,707 | 20.9 K to 21.7 K (+3.89 %) |
| Jul 03 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Grant | A | 20.04 | 430 | 8,618 | 3,310 | 2.9 K to 3.3 K (+14.93 %) |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | MOSCICKI RICHARD A | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | PARSHALL B LYNNE | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | Hochberg Elaine | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | SMITH SANDFORD D | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | FITZGERALD EDWARD M | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Jun 18 2019 | AKCA | AKCEA THERAPEUTICS ... | GABRIELI CHRISTOPHER | Director | Option Exercise | A | 22.74 | 26,400 | 600,336 | 26,400 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 20,000 | 129,600 | 302,250 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 30,000 | 194,400 | 322,250 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Sell | S | 31.72 | 20,000 | 634,418 | 2,880 | 22.9 K to 2.9 K (-87.41 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 20,000 | 129,600 | 22,880 | 2.9 K to 22.9 K (+694.44 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Sell | S | 31.71 | 30,000 | 951,300 | 2,880 | 32.9 K to 2.9 K (-91.24 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 30,000 | 194,400 | 32,880 | 2.9 K to 32.9 K (+1,041.67 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 1,787 | 11,580 | 1,711,079 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 30,000 | 194,400 | 1,712,866 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Sell | S | 32.17 | 1,787 | 57,480 | 0 | 1.8 K to 0 (-100.00 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 1,787 | 11,580 | 1,787 | 0 to 1.8 K |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Sell | S | 32.11 | 30,000 | 963,300 | 0 | 30 K to 0 (-100.00 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 30,000 | 194,400 | 30,000 | 0 to 30 K |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 20,000 | 129,600 | 302,250 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Option Exercise | M | 6.48 | 30,000 | 194,400 | 322,250 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Sell | S | 31.72 | 20,000 | 634,418 | 2,880 | 22.9 K to 2.9 K (-87.41 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 20,000 | 129,600 | 22,880 | 2.9 K to 22.9 K (+694.44 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Sell | S | 31.71 | 30,000 | 951,300 | 2,880 | 32.9 K to 2.9 K (-91.24 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Goldberg Jeff Marc | Chief Operating Off ... | Buy | M | 6.48 | 30,000 | 194,400 | 32,880 | 2.9 K to 32.9 K (+1,041.67 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 1,787 | 11,580 | 1,711,079 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 30,000 | 194,400 | 1,712,866 | |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Sell | S | 32.17 | 1,787 | 57,480 | 0 | 1.8 K to 0 (-100.00 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 1,787 | 11,580 | 1,787 | 0 to 1.8 K |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Sell | S | 32.11 | 30,000 | 963,300 | 0 | 30 K to 0 (-100.00 %) |
| Apr 09 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Buy | M | 6.48 | 30,000 | 194,400 | 30,000 | 0 to 30 K |
| Apr 02 2019 | AKCA | AKCEA THERAPEUTICS ... | IONIS PHARMACEUTICALS INC | 10% Owner | Buy | J | 0.00 | 2,837,373 | 0 | 70,221,338 | 67.4 M to 70.2 M (+4.21 %) |
| Mar 07 2019 | AKCA | AKCEA THERAPEUTICS ... | Soteropoulos Paula | Chief Executive Off ... | Option Exercise | M | 6.48 | 18,386 | 119,141 | 1,742,866 |